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Orange juice consumption and its eﬀect on blood
lipid proﬁle and indices of the metabolic
syndrome; a randomised, controlled trial in an
at-risk population
E. J. Simpson,*a B. Mendisb and I. A. Macdonalda
Data from epidemiological and in vitro studies suggest that orange juice (OJ) may have a positive impact
on lipid metabolism. However, there have been reports in the media claiming detrimental consequences
of 100% juice consumption, including weight-gain and adverse eﬀects on insulin sensitivity and blood
lipid proﬁle. The eﬀect of daily OJ consumption was assessed using a randomised, placebo-controlled,
single-blinded, parallel group design. Thirty-six overweight, but otherwise healthy men (40–60 years;
27–35 kg m−2) with elevated fasting serum cholesterol (5–7 mmol l−1), were recruited from the general
UK population. None were using nutritional strategies or medication to lower their cholesterol, nor were
regular consumers of citrus products. Assessment of BMI, HOMA-IR, and circulating lipid (total chole-
sterol, low-density lipoprotein, high-density lipoprotein, non-esteriﬁed fatty acids, triacylglycerol, apolipo-
protein-A1 and apolipoprotein-B) concentrations, was made when fasted before (V1) and after a 12-week
intervention (V2), during which participants consumed 250 ml per d of OJ or an energy and sugars-
matched orange-ﬂavoured drink (control). The two groups were matched at V1 with respect to all para-
meters described above. Although triacylglycerol concentration was similar between the groups at both
visits, a trend for the change in this variable to diﬀer between groups was observed (P = 0.060), with
those in control exhibiting a signiﬁcant increase in triacylglycerol at V2, compared with V1. In OJ, those
with the highest initial triacylglycerol concentration showed the greatest reduction at V2 (R2 = 0.579; P <
0.001), whereas there was no correlation between these variables in controls (R2 = 0.023; P = 0.548).
Twelve weeks consumption of 250 ml per d of OJ did not adversely aﬀect insulin sensitivity, circulating
lipids or body weight.
Introduction
With the current global epidemic of obesity and associated co-
morbidities, there is interest in the contribution of dietary
factors to the development and alleviation of obesity and meta-
bolic syndrome, including cardiovascular risk factors such as
hypercholesterolemia and hypertriacylglycerolemia. Dysregula-
tion of lipid and lipoprotein metabolism can contribute to the
development of atherosclerosis and cardiovascular disease,1
and systematic reviews have indicated that improvement of
the serum lipid profile can reduce mortality related to
atherosclerosis.2
Regular consumption of soda drinks containing high-fruc-
tose corn syrup and sucrose has been suggested as a risk
factor in the development of obesity in children3 and some
researchers have expressed concern that a high dietary intake
of 100% juice may also contribute to the development of
obesity and the metabolic syndrome in adults, the latter
perhaps due to increased fructose consumption.4 However, a
relationship between 100% juice consumption and adverse
metabolic consequences is not universally accepted,5,6 with
epidemiological surveys, such as the NHANES, suggesting that
consumption of fruit juice is associated with lower BMI
and reduced indices of the metabolic syndrome, including
circulating total cholesterol concentration.7,8 Despite the
sugars content of 100% juice, it is proposed that characteri-
stics of fruit juice, not found in sweetened beverages, in
particular phenolic compounds and flavonoids, may be pro-
tecting individuals from adverse metabolic eﬀects. Indeed,
lower fasting total and Low Density Lipoprotein (LDL) chole-
sterol, and Apolipoprotein B (Apo-B) have been observed
in daily consumers of orange juice compared with non-
consumers.9
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In vitro studies, using isolated liver cells, have shown that
citrus flavonoids can reduce net Apo-B secretion, by inhibiting
synthesis of the cholesterol esters required for LDL pro-
duction.10 This LDL lowering eﬀect of purified citrus flavo-
noids is supported by in vivo supplementation studies in
rodents,11–13 rabbits,14 and humans,15 and the presence of
these flavonoids in orange juice (the most commonly con-
sumed 100% juice in the US) may contribute to the obser-
vation of reduced serum total cholesterol concentration
measured in epidemiological studies.8 However, prospective
data from humans supplementing their diet with 100% orange
juice are limited and equivocal. Short-term, high-dose con-
sumption (750 ml d−1 for 4–8 weeks), in hypercholesterolemic
patients, has been shown to lower serum LDL concentrations16
or have no eﬀect on this parameter,17 with high-density lipo-
protein cholesterol (HDL) concentration in these patients
being unaﬀected by supplementation in the former study16
but increased in the latter.17 However, the above studies were
potentially compromised by the lack of blinding, supplemen-
tation in conjunction with other dietary advice, and the
absence of a placebo control drink. Moreover, supplementing
the diet with 750 ml of orange juice per day, is equivalent
to adding 5 UK recommended portions of 100% juice,18 and
provides approximately 60 g of sugars plus an extra 1 MJ in
dietary energy intake. Increasing dietary intake of sugars,
when in positive energy balance, has been associated with
detrimental changes to the circulating lipid profile in humans.19
It is therefore important for any lipid-modifying eﬀects of
orange juice consumption to be assessed prospectively at a
daily intake which is more representative of UK consumption
guidelines. Kurowska et al. did not observe any statistical
improvement in blood lipid profile after a month’s supplemen-
tation with 250 ml of orange juice a day.17 However, a 5%
increase in circulating HDL concentration was observed, which
may be further increased over a longer time frame.
The current study investigated the eﬀect of 3 month’s daily
consumption of 250 ml of orange juice on lipid profile, body
weight and fasting insulin sensitivity in overweight men with
elevated serum total cholesterol concentration. A sugars- and
energy-matched control drink was used to standardise for
any potential confounding eﬀect of increasing dietary
sugars and energy intake on variables, and to investigate any
positive eﬀects that may be associated with orange juice
consumption.
Results
Participants
Initial interest was expressed by 280 men, 71 of whom fulfilled
inclusion criteria (except elevated total serum cholesterol con-
centration), and undertook a medical screening. In total, 36 of
these individuals were suitable to participate and were ran-
domly assigned into either the orange juice (OJ) or control
(CON) group, with groups being matched for age (OJ: 48.3(3.9)
y, CON: 48.9(4.3) y; P = 0.627). No participants withdrew from
the study.
Anthropometry
Groups were matched at baseline with respect to body weight
(P = 0.988), and the intervention did not result in a change in
this variable (Table 1; P = 0.807). At the start of the study, all
participants were either overweight or grade 1 obese (OJ: 29.9
(2.3) kg m−2, CON: 29.3 (1.7) kg m−2), with mean BMI being
similar between the groups (P = 0.370). Waist and hip circum-
ference and % total body fat of the participants reflect the
overweight nature of the group, and the group mean waist : hip
ratios were at values reported to confer an increased risk of
developing cardiovascular disease.20 These variables were
matched between groups at visit 1 (waist: P = 0.560; hip:
P = 0.541; waist : hip ratio: P = 0.971; % total body fat: P =
0.792) and were unaﬀected by the intervention (waist: P =
0.619; hip: P = 0.760; waist : hip ratio: P = 0.888; % total body
fat: P = 0.556).
Fasting insulin sensitivity
Participants were not recruited on the basis of demonstrating
insulin resistance, (with respect to fasting glucose and insulin
concentration). However, as with other overweight cohorts
reported in the literature, HOMA-IR values indicative of fasting
insulin resistance were observed (Table 1). Groups were
matched for HOMA-IR pre-intervention (P = 0.546) and this
measure did not change as a result of the supplementation
period (OJ: P = 0.586, CON: P = 0.609).
Table 1 Mean (unless otherwise indicated) values for anthropometric, BP and fasting insulin resistance parameters. Mean data display the SD in par-
entheses and median data show the 25th and 75th percentile in parentheses. Comparison of groups at baseline, and the change seen after the inter-
vention, between groups, was P > 0.05 for each variable
OJ (n = 18) CON (n = 18)
Pre-intervention Change at week 12 Pre-intervention Change at week 12
Body weight (kg) 96.3(9.91) −0.32(2.85) 94.9(8.19) −0.13(1.76)
Waist circumference (cm) 105.1(6.16) 0.06(2.80) 104.1(4.47) −0.44(3.17)
Hip circumference (cm) 109.8(5.36) 0.39(5.03) 108.8(4.59) −0.03(2.76)
Waist : hip 0.96(0.05) −0.003(0.04) 0.96(0.04) −0.005(0.03)
Total body fat (kg) 26.39(5.86) −0.19(2.24) 28.82(4.94) −0.39(1.78)
Total body fat (%) 33.36(5.37) −0.14(1.55) 33.78(4.05) −0.44(1.54)
Median HOMA-IR 3.5(2.4–4.3) 0.0(−1.3–0.63) 3.2(2.6–4.4) 0.0(−0.7–0.9)
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Incretin hormones and leptin
Circulating PYY, Ghrelin, GLP-1 and leptin concentration,
when fasted, were similar between the groups at V1 (P = 0.673,
0.767, 0.481 and 0.839 respectively; Table 2). No changes to
PYY (P = 0.500), ghrelin (P = 0.472) or leptin (P = 0.112)
occurred as a result of OJ, although there was a trend for
GLP-1 to be reduced in this group (P = 0.081). In CON, no
changes in these variables were observed (PYY: P = 0.616,
ghrelin: P = 0.420, GLP-1: P = 0.760, leptin: P = 0.360). When
OJ was compared to CON, no intervention eﬀect of orange
juice consumption was observed for PYY (P = 0.815), ghrelin
(P = 0.279), or GLP-1 response (P = 0.226), although there was a
weak trend for the change in leptin to be diﬀerent (P = 0.097).
Inflammatory markers and uric acid
At V1, circulating TNFα was significantly higher (P = 0.034),
CRP markedly lower (P = 0.019) and a trend for IL-6 to be
higher (P = 0.083) in the OJ group (Table 2). However, these
variables did not change as a result of either intervention
(P ≥ 0.312 in each case) and there was no diﬀerence in the
changes at week 12 between groups (TNFα: P = 0.959, IL-6: P =
0.987 and CRP: P = 0.118). Fasting uric acid concentration was
similar between groups at V1 (P = 0.661) and did not change as
a result of the interventions (OJ: P = 0.179, CON: P = 0.813).
Moreover, no diﬀerence in UA response to the interventions,
between groups was noted (P = 0.303).
Lipids
Participants were selected on the basis of having a total chole-
sterol concentration of between 5 and 7 mmol l−1, and this
was reflected in the mean fasting total cholesterol values being
above the healthy range, but below a concentration which
would require therapeutic intervention. The 2 groups were
similar with regards to serum lipid and lipoprotein concen-
trations pre-intervention, including; total cholesterol (P =
0.207), LDL (P = 0.085), HDL (P = 0.839), NEFA (P = 0.805), Apo-
A1 (P = 0.963) and Apo-B (P = 0.126; Table 3). These parameters
did not change significantly across visits within groups, and
no diﬀerences were observed between groups, over the inter-
vention period (P > 0.05).
Although median TAG concentration of both groups was
comparable at V1 (P = 0.839) and V2 (P = 0.613), there was a
trend for the change in this variable to be diﬀerent between
the groups after the intervention period (P = 0.060), with
fasting TAG being significantly higher at V2 in controls
(P < 0.05). Although median TAG was numerically lower in the
OJ group at V2, compared with V1, this was not statistically
significant or notable in terms of a trend. However, in the OJ
group, those with the highest initial triacylglycerol concen-
tration pre-intervention, showed the greatest reduction after
12 weeks supplementation, whereas there was no correlation
between these variables in the control group (Fig. 1). There
were also no significant associations observed between the
change in dietary carbohydrate, total sugars or energy intake
Table 2 Median (unless otherwise indicated) concentration of circulating variables sampled in the fasted state before and at week 12 of the inter-
vention. Median data show the 25th and 75th percentile in parentheses and mean data display the SD in parentheses
OJ (n = 18) CON (n = 18)
Pre-intervention Change at week 12 Pre-intervention Change at week 12
PYY (pg ml−1) 86.8 (77.8–107.6) 6.7 (−9.5–13.7) 99.1 (71.0–118.8) 0.7 (−7.9–12.6)
Ghrelin (pg ml−1) 797.9 (722.7–1096.8) −9.1 (−62.5–117.3) 933.7 (763.7–1056.9) 25.0 (−103.9–62.4)
GLP-1 (pmol l−1) 2.24 (1.94–4.00) −0.14 (−0.77–0.43) 2.32 (1.16–3.49) −0.02 (−0.43–0.56)
Leptin (ng ml−1) 7.88 (6.81–14.36) −0.58 (−1.99–0.57) 8.23 (6.88–12.62) 0.32 (−1.03–1.85)
CRP (pg ml−1) 0.91a (0.48–1.77) 0.13 (−0.21–0.66) 1.86 (1.08–3.74) 0.01 (−1.29–0.90)
IL-6 (pg ml−1) 3.93 (2.23–5.94) 0.00 (−0.94–0.82) 2.33 (2.09–3.27) 0.00 (−0.95–1.01)
TNFα (pg ml−1) 3.24a (2.34–3.88) −0.06 (−0.84–0.41) 2.22 (1.69–3.01) 0.00 (−0.99–0.89)
Mean UA (μmol l−1) 376.7(72.54) 15.6(47.10) 387.1(68.07) −3.4(60.93)
a P < 0.05 compared to control group at pre-intervention.
Table 3 Lipid parameters. Data are the median with the 25th and 75th percentile displayed in parentheses. Comparison of groups at baseline, and
the change seen after the intervention, between groups, was P > 0.05 for each variable
OJ (n = 18) CON (n = 18)
Pre-intervention Change at week 12 Pre-intervention Change at week 12
Total cholesterol (mmol l−1) 5.62 (5.22–6.53) 0.02 (−0.54–0.36) 6.21 (5.78–6.63) 0.23 (−0.32–0.33)
LDL (mmol l−1) 3.64 (3.38–4.24) 0.04 (−0.33–0.33) 4.20 (3.65–4.53) −0.01 (−0.41–0.22)
HDL (mmol l−1) 1.11 (1.03–1.34) −0.02 (−0.11–0.08) 1.17 (1.04–1.37) −0.02 (−0.05–0.03)
NEFA (mmol l−1) 0.39 (0.32–0.56) −0.08 (−0.19–0.02) 0.44 (0.31–0.55) −0.02 (−0.18–0.08)
Apo-A1 (g l−1) 1.23 (1.10–1.28) 0.06 (−0.04–0.09) 1.22 (1.10–1.32) 0.01 (−0.04–0.08)
Apo-B (g l−1) 1.08 (1.04–1.26) 0.06 (−0.10–0.10) 1.27 (1.10–1.36) 0.02 (−0.11–0.07)
TAG (mmol l−1) 1.52 (0.93–2.30) −0.11 (−0.68–0.53) 1.47 (1.04–2.60) 0.29 (−0.07–0.72)
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after 12 weeks supplementation, and the change in serum TAG
concentration, in either group. Spearman’s rho was 0.345 (P =
0.227), 0.213 (P = 0.464), and 0.165 (P = 0.573) respectively in
the OJ participants, and 0.016 (P = 0.957), −0.066 (P = 0.831)
and −0.462 (P = 0.112) respectively in the control group.
Indeed, the trend for the change in TAG to be diﬀerent,
between the groups, after the intervention period, remained
when sugars intake at V1 was used as a covariate (P = 0.076).
However, when either dietary energy or carbohydrate intake at
V1 were used as a covariate, this trend was no longer present
(P = 0.110 and P = 0.103, respectively).
Dietary intake
Complete diet diaries were obtained for 33 out of 36 partici-
pants (Table 4). When compared with CON, those in the OJ
group reported a greater intake of carbohydrate (P < 0.005) and
total sugars (P < 0.01) before the intervention period, and this
was reflected in the latter showing higher daily energy intake
(P < 0.05). Indeed, at baseline, total sugars contributed a
greater percentage of daily energy in the OJ group, compared
with the control group (P < 0.05). However, despite daily con-
sumption of OJ, the amount of sugars consumed and percen-
tage of dietary energy intake derived from total sugars reported
at week 11 did not change (P = 0.686 and P = 0.950 respecti-
vely), suggesting that participants in this group were compen-
sating for the extra 22 g of total sugars provided by the orange
juice, by reducing consumption of other products containing
sugars. Indeed, daily energy intake at week 11 in this group
was reduced compared to pre-intervention (P < 0.05), although
the macronutrient composition of the diet did not appear to
be aﬀected by this reduction in energy intake. In the control
group, neither reported daily energy intake, nor macronutrient
composition of the diet changed as a result of the intervention
(P > 0.05 in each case; Table 4). However, there was a diﬀer-
ence, between groups, in the eﬀect of the interventions on
both daily intake of carbohydrate and proportion of total
energy provided by carbohydrate (P < 0.05).
Discussion
Media reports have claimed that regular 100% juice consump-
tion adversely eﬀects body weight, insulin sensitivity and
blood lipid profile. This study did not observe detrimental con-
sequences of 12 weeks daily orange juice consumption in any
of these parameters. Review of fructose, and other simple
sugars, feeding studies suggests that it is likely to be the over-
feeding of energy which can occur with supplementation proto-
cols, rather than ingestion of the sugars per se which confers
detrimental metabolic eﬀects.19,21 In the current study, partici-
pants appeared to be in energy balance, as body weight did
not increase as a result of either intervention. The absence of
an increase in body weight has been noted in other studies
supplementing the diet with citrus juice,16,17,22 although 100%
juice consumption does not appear to suppress appetite to a
greater extent than non-juice beverages containing sugars,23
and in the current study convincing evidence for increased
satiety signalling, based on fasting incretin hormone profiles
in the 2 groups, was not observed.
Fig. 1 Correlation between pre-intervention TAG concentration (at V1)
and change in TAG concentration (from V1) over the 12 week interven-
tion (n = 18 in each group). OJ group R2 = 0.579 (P < 0.001), control
group R2 = 0.023 (P = 0.548).
Table 4 Mean (unless otherwise indicated) reported daily macronutrient intake and macronutrient composition of the diet (expressed as % of total
energy intake) for 33 participants. Median data show the 25th and 75th percentile displayed in parentheses, and mean data display the SD in
parentheses
OJ (n = 17) CON (n = 16)
Pre-intervention Change at week 11 Pre-intervention Change at week 11
Median protein intake (g) 103.0 (78.5–121.1) −7.4 (−21.7–8.9) 92.2 (77.7–106.3) −8.6 (−14.4–9.5)
Fat intake (g) 131.3(35.2) −10.2(32.2) 119.6(36.4) −10.7(34.6)
CHO intake (g) 348.9(72.9)a −33.1(72.9)b 257.9(60.7) 23.1(63.9)
Total sugars intake (g) 144.2(52.7)a −5.4(54.6) 99.0(38.5) 8.57(37.7)
Total energy intake (MJ) 13.1(2.86)a −1.32(2.39) 10.9(2.70) −0.53(2.14)
Median % total energy (E) derived from protein 13.6 (11.3–14.8) 0.7 (−0.55–1.95) 14.8 (13.7–15.9) 0.2 (−2.98–1.95)
% E from fat 37.8(6.42) 1.13(5.11) 40.9(5.13) −1.94(6.98)
% E from CHO 42.2(7.16) −0.14(4.13)b 37.7(6.31) 5.08(8.14)
% E from sugars 18.6(4.88)a −0.07(4.21) 14.3(4.22) 1.81(5.17)
a P < 0.05 compared to control group pre-intervention. b P < 0.05 compared to control group, for change at week 11.
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Strengths of the current study were the use of an energy
and sugars matched control drink (to isolate any diﬀerence
between 100% juice and a sweetened beverage) and a single-
blinded study design (to identify any placebo eﬀect of partici-
pating in the study). Participants were not aware that 100%
juice was being investigated and did not know whether they
had been randomised to the drink containing citrus flavonoids
or no citrus flavonoids. In previous studies examining the
eﬀect of OJ consumption on lipid parameters, participants
were not blinded to the drink being consumed, which may
have altered their health behaviours and had an impact on
outcomes. However, in the current study, 12 weeks daily sup-
plementation of the diet with the control drink did not result
in significant increases in body weight, insulin resistance, or
circulating cholesterol. It is therefore not possible to deter-
mine whether phenolic compounds and flavonoids found in
fruit juice can protect individuals from these purported
adverse metabolic eﬀects of consuming drinks containing
sugars.
In the present study, components within orange juice may
have mitigated the negative eﬀect of regular sweet drink con-
sumption on circulating TAG concentration, and may have pro-
moted a reduction in this variable in those who demonstrated
hypertriacylglycerolemia at V1. Although the observed eﬀects
of interventions on circulating TAG are statistically under-
powered, the impact that OJ consumption could be having on
TAG concentration in the current study supports findings from
rodent and human studies which have supplemented the diet
with purified flavonoids.13,24 However, observations are not
consistent with other human in vivo studies supplementing
with whole juice, which have observed no change in TAG con-
centration after 4 weeks when up to 500 ml per d of orange
juice have been provided,17,22 but an increase when partici-
pants consumed 750 ml d−1.17 Our data and that of Miwa
et al.24 suggest that the lowering eﬀect of orange juice, or
citrus flavonoid, supplementation on circulating TAG is not
observed where plasma TAG concentration is within the
healthy range, and might explain why improvements in TAG
concentration were not seen in normotriacylglycerolemic
individuals in the Morand study.22
A criticism of the current study is that despite a randomised
design, the OJ group reported greater carbohydrate, total
sugars and dietary energy intake than the control group before
the intervention began, and covariate analysis suggested that
carbohydrate and/or energy intake at V1 may have had an
impact on the subsequent response of circulating TAG to the
interventions. Increasing the proportion of carbohydrate in the
diet has been associated with a rise in plasma TAG concen-
tration,25 and in the current study the change in dietary carbo-
hydrate intake at week 11 of supplementation in the OJ group,
compared with that in controls, may have contributed to the
observed trend for the change in circulating TAG to be
diﬀerent at V2 between groups. Furthermore, although there
appears to be a genetic component to this observation, over-
feeding energy has also been shown to increase plasma TAG
concentration26 and the reduction in dietary energy intake
observed in the OJ group may have had an impact on this vari-
able. However, overfeeding is generally accompanied by modi-
fications to other lipid measures, such as increased LDL and
ApoB, and decreased HDL,26 and changes to these variables
were not observed. Indeed, changes in reported energy intake
were not reflected in any significant alterations to body weight
in these cohorts, and it is possible that recording dietary
intake over 3 days was not suﬃcient to truly reflect the habit-
ual diet, as has been reported by others.27 Further investi-
gation, with more detailed dietary intake measures, is required
to determine the potential confounding eﬀect of macro-
nutrient composition and energy balance on the TAG modify-
ing eﬀects of orange juice supplementation.
Previous studies have reported a LDL-lowering eﬀect of
orange juice and citrus flavonoid supplementation in
man,15,24,28 but this is not a universal finding.17,29 Indeed, no
change in LDL concentration was observed in the current
study. Data from in vitro research suggest that the LDL modify-
ing ability of citrus juices is mediated through their flavonoid
components.10 It is therefore possible that the failure to
improve LDL profile in the current investigation was due to the
amount of flavonoids provided being too low; studies reporting
improvements in LDL concentration with daily intake of
purified flavonoids, have supplemented the diet of partici-
pants with approximately 0.7 mmol of glucosyl hesperidin or
naringin (naringenin 7-O-rhamnoglucoside),15,24 whereas the
amount provided by the orange juice in the present study was
approximately 0.22 mmol of hesperidin and 0.03 mmol of
narirutin (naringenin-7-O-rutinoside) per day. However, data
in the literature do not provide evidence for this supposition.
The reported quantity of flavonoids provided by daily con-
sumption of 750 ml of orange juice, in a study which induced
a reduction in LDL concentration, was of a similar magnitude
to that provided in the current study (0.14 mmol hesperitin
and 0.02 mmol naringin),16 and daily supplementing the diet
with greater amounts (1.3 mmol hesperidin or 0.86 mmol
naringin) did not result in any improvements to circulating
lipids in those with elevated cholesterol.29 It is therefore diﬃcult
to identify a clear explanation for the diﬀerences in LDL response
to citrus juice and purified citrus flavonoid supplementation
seen in the in vivo human studies, but statistical power, varia-
bility in study design (including absence of placebo control),
quantity of juice or flavonoids used, supplementation dur-
ations, character of participant cohorts, habitual diet, fibre
content, or the forms of citrus flavonoids being used (glyco-
side vs. aglycone), may all play a part. Further investigation of
these confounding factors may help to clarify any potential
health benefit of citrus consumption.
Experimental
Trial design
A randomised, single-blinded, placebo controlled, parallel
group study design was used. The random allocation sequence
was generated using an on-line calculator30 with the number
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of individuals in each group balanced in 3 blocks (12 indivi-
duals per block; 6 OJ and 6 control). Blocks were used to
promote participants of each group being on the trial at
similar times of the year, to mitigate any confounding eﬀects
of seasonal variation in habitual diet. Individuals were ran-
domised at the point of entering the study, with their partici-
pant number allocated sequentially.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the University of
Nottingham Medical School Ethics Committee. Written
informed consent was obtained from all subjects, and the pro-
tocol was registered at http://www.clinicaltrials.gov reference
NCT01350843.
Participants
Thirty-six overweight, or mildly obese men (BMI 27–35 kg m−2;
aged 40–60 years) who were otherwise healthy, were recruited
from the general population of Nottinghamshire, UK. All par-
ticipants attended the David Greenfield Human Physiology
Unit (Queen’s Medical Centre, Nottingham, UK) for an initial
medical screening visit to confirm health status. In addition,
blood pressure (BP) was measured at the left upper arm (after
lying semi-supine for 5 min) using automated oscillometry
(Dynamap Pro 1000; GE Medical, Milwaukee, USA). BMI was
calculated from measured height and weight. If participants
were suitable to take part with regards to their health question-
naire and BMI measures, a venous blood sample was then
taken to assess fasting lipid concentration. Those taking lipid-
lowering medication, or who reported using nutritional strat-
egies to lower their cholesterol, were excluded. Participants
were accepted onto the trial if their serum total cholesterol
concentration was between 5–7 mmol l−1, they did not
consume citrus juice or whole fruit on a daily basis, they did
not have any food allergies related to the investigational
product, and did not demonstrate any clinically significant
abnormalities on screening. Eligibility criteria were not altered
during the recruitment period.
Intervention
After recruitment, participants were asked to record all food
intake (including snacks and drinks) in a diet diary for 3 days
(2× week or work days, and 1× weekend or rest day) for baseline
assessment of macronutrient and energy intake, and to attend
the David Greenfield Human Physiology Unit for 2 further
visits (at weeks 0, and 12). These visits took place in the
morning after the individual had fasted from midnight the
night before. Initially, measurement of body mass was made
to the nearest 0.1 kg using a Seca 882 Digital Scale (Birming-
ham, UK), and waist and hip circumference were assessed
(with the participant standing) mid-way between the lowest rib
and the iliac crest, and at the greater trochanters, respectively.
Participants were then asked to rest, semi-supine, on a couch
for 5 min before having their resting BP measured, as pre-
viously described. A fasting blood sample was taken for deter-
mination of serum insulin, leptin, uric acid (UA), TNFα,
C-Reactive Protein (CRP), interleukin-6 (IL-6), total cholesterol,
HDL, LDL, apolipoprotein A1(Apo-A1), and Apo-B, plasma PYY,
ghrelin, glucagon-like protein (GLP-1), TAG and non-esterified
fatty acids (NEFA), and whole blood glucose. Whole blood
glucose was immediately assessed using the glucose hydro-
genase photometric method (Hemocue, Agelholm, Sweden;
within assay precision being 1.41%), with other samples
frozen at −80 °C and stored until analysis at a later date.
Participants were asked to consume 250 ml of either orange
juice (as frozen concentrate orange juice; FCOJ, provided by
Florida State Department of Citrus, USA, and diluted 1 part
concentrate to 3 parts water before consumption; FCOJ was
42° Brix and reconstituted OJ was 11.8° Brix), or an energy and
sugars matched, orange-flavoured control drink (MPBioscience
Ltd, Derby, UK), once a day for 12 weeks. Participants in the OJ
group were provided the FCOJ, a measuring jug and storage
vessel for the reconstituted drink. Instructions on how to
reconstitute the juice before consumption and how to store
both the frozen and reconstituted drink were also provided.
The quantity consumed was chosen to reflect the average
volume of 100% juice portions available commercially in the
UK (which range from 200 ml–330 ml), and allow comparison
with previous studies. A sugars matched control was selected
to identify any confounding eﬀects that supplementing the
diet with additional sugars and energy may have. The compo-
sition of the drinks is shown in Table 5, and the citrus flavo-
noids contained in the orange juice reflect their natural
abundance in the product.
The 12 week supplementation period began on the day
after the first study visit. In all documentation and interaction
with participants, the products were described as an ‘orange
flavoured drink’ which was either rich in citrus polyphenols or
low in these compounds. The study was therefore single
blinded; those providing drink supplies to participants knew
which product participants received, but participants and
those executing the biochemical analysis were blinded. Weekly
telephone contact with the study participants was maintained
over the dosing period to improve compliance. No problems
with the supplementation protocol or the palatability of the
drinks were reported by participants.
Individuals were asked to complete a further 3-day diet
diary (as previously described) in the week before the second
study visit (week 11), to assess any changes in macronutrient
or energy intake which may have occurred as a consequence of
the intervention. Household measures were used to estimate
Table 5 Composition of drinks, with regards to sugars, vitamin C and
citrus ﬂavonoids contained in one 250 ml serving
Orange juice Control drink
Sucrose (g) 10.78 11.66
Fructose (g) 5.60 5.87
Glucose (g) 5.25 4.95
Vitamin C (mg) 137 90
Hesperidin (mg) 135.4 0
Narirutin (mg) 15.5 0
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portion size, and diaries were subsequently analysed using a
food composition database (WISP V2, Tinuviel Software UK
2003). To calculate habitual diet composition, a mean daily
intake was obtained from all 3 days of each recording period,
and macronutrient composition was expressed as a percentage
of total energy intake. These data were combined to produce
group means.
Analytical methods
Serum insulin was assessed using a human-specific radio-
immunoassay (Merck Millipore, Billerica, MA, USA), with an
intra-assay coeﬃcient of variation (CV) of 4.41%, and an inter-
assay CV of 10.53%. NEFA was analysed by the ACS-ACOD
method (Wako Diagnostics, Richmond, VA, USA), and had an
intra-assay CV of 0.65%, an inter-assay CV of 2.95%. TAG, total
cholesterol, LDL and HDL were measured using enzymic
photometric methods (Horiba Medical, Montpellier, France),
and the intra-assay CVs were 2.16%, 2.63%, 2.21% and 0.77%
respectively, with inter-assay CVs being 3.27%, 2.6%, 4.77%
and 4.72%. Apo-A1 and Apo-B were analysed using enzymic
turbidimetric methods (Horiba Medical, Montpellier, France)
and within assay precision for these assays were 0.86% and
1.96% with between assay precision being 1.33% and 1.96%,
respectively.
Statistical methods
All data were coded and analysed using SPSS version 16.0
(Statistical Package for the Social Sciences 2000). Data were
initially checked for normality of distribution (using criteria of
skewness or kurtosis z-score between −1.96 and 1.96). Para-
metric data are described in the text and tables as the mean
with the standard deviation in parentheses, with non-para-
metric data displayed as the median with the 25% to 75%
quartile range shown in parentheses. Group characteristics at
baseline were compared between groups using unpaired
students t-test or non-parametric equivalent (Mann–Whitney
U) as appropriate. Within group comparisons of variables
measured at baseline (week 0) and at the end of intervention
(week 12), were investigated using paired Student’s t-test, or a
non-parametric equivalent (Wilcoxon signed ranks). To assess
the eﬀect of intervention on variables, a mixed model ANOVA
with repeated measures was used. Violation of the assumption
of sphericity was assessed using Mauchly’s test, and where
appropriate the Greenhouse-Geisser statistic was used to deter-
mine the P value. All analysis used a two-tailed assessment
and statistical significance was assumed where P < 0.05.
Sample size
Using data generated from the Cesar et al. (2010) to inform the
variability of LDL-cholesterol concentration in a hypercholes-
terolemic population, and a parallel study design with 18 in
each group (OJ vs. carbohydrate matched control), this would
give the statistical power to detect a diﬀerence in mean LDL
cholesterol of 0.5 mmol l−1 (21 mg dl−1), which is the magni-
tude of change reported in hypercholesterolemic patients after
orange juice consumption.16
Conclusions
Daily consumption of 250 ml of orange juice for 3 months did
not result in an increase in dietary sugars intake in a cohort of
overweight men with elevated total cholesterol concentration,
and despite media concern, an increase in body weight or
decreased insulin sensitivity did not occur over the inter-
vention. Moreover, regular orange juice consumption did not
adversely aﬀect fasting blood lipids, and may help reduce
elevated plasma triacylglycerol concentration. However,
changes in carbohydrate and/or dietary energy intake observed
during the supplementation period are likely to have con-
founded this latter observation.
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